Completion Rate and Side-Effect Profile of Three-Month Isoniazid and Rifapentine Treatment for Latent Tuberculosis Infection in an Urban County Jail

被引：16

作者：

Juarez-Reyes, Maria ^{[1
]}

Gallivan, Mark ^{[2
]}

Chyorny, Alexander ^{[3
]}

O'Keeffe, Linda ^{[3
]}

Shah, Neha S. ^{[2
,4
]}

机构：

[1] Stanford Univ, Sch Med, 3250 Alpine Rd, Portola Valley, CA 94028 USA

[2] Calif Dept Publ Hlth, Richmond, CA USA

[3] Santa Clara Valley Med Ctr, Custody Hlth Serv, San Jose, CA 95128 USA

[4] Ctr Dis Control & Prevent, Atlanta, GA USA

来源：

OPEN FORUM INFECTIOUS DISEASES | 2016年 / 3卷 / 01期

关键词：

correctional healthcare; prevention; tuberculosis;

D O I：

10.1093/ofid/ofv220

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In an urban jail population, 3 months of isoniazid and rifapentine (3HP) was associated with an 85% latent tuberculosis infection treatment completion rate compared with 18% in a standard 9 -month isoniazid treatment group. Among the 91 patients who started 3HP therapy, there were 2 treatment discontinuations from adverse drug reactions.

引用

页数：3

共 12 条

[1] Isoniazid preventive therapy in correctional facilities: a systematic review [J].

Al-Darraji, H. A. A. ;

Kamarulzaman, A. ;

Alticet, F. L. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2012, 16 (07) :871-879

[2] Tuberculosis outbreak in a Texas prison, 1994 [J].

BergmireSweat, D ;

Barnett, BJ ;

Harris, SL ;

Taylor, JP ;

Mazurek, GH ;

Reddy, V .

EPIDEMIOLOGY AND INFECTION, 1996, 117 (03) :485-492

[3]

*CDCP, 1996, MMWR MORB MORTAL WKL, V45

[4]

Centers for Disease Control and Prevention (CDC), 2013, MMWR Morb Mortal Wkly Rep, V62, P904

[5]

Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P1

[6] Jails, a neglected opportunity for tuberculosis prevention [J].

MacNeil, JR ;

McRill, C ;

Steinhauser, G ;

Weisbuch, JB ;

Williams, E ;

Wilson, ML .

AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2005, 28 (02) :225-228

[7]

Miramontes R, 2013, MMWR-MORBID MORTAL W, V62, P201

[8]

National Correctional Healthcare Association, 2002, HLTH STAT SOON TO BE, V1, P5

[9] Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts [J].

Schechter, M ;

Zajdenverg, R ;

Falco, G ;

Barnes, GL ;

Faulhaber, JC ;

Coberly, JS ;

Moore, RD ;

Chaisson, RE .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (08) :922-926

[10] Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States [J].

Shepardson, D. ;

Marks, S. M. ;

Chesson, H. ;

Kerrigan, A. ;

Holland, D. P. ;

Scott, N. ;

Tian, X. ;

Borisov, A. S. ;

Shang, N. ;

Heilig, C. M. ;

Sterling, T. R. ;

Villarino, M. E. ;

Mac Kenzie, W. R. .

INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (12) :1531-1537

← 1 2 →